Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports
Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports
复制标题
阿立哌唑、苯海索和肉毒毒素联合治疗节段性颅颈肌张力障碍（Meige综合征）：三例报告
DOI：
10.1007/s10072-014-1927-x
复制
发表时间：
2015
影响因子：
3.3
通讯作者：
N. Hasebe
中科院分区：
文献类型：
--
作者：
Tsukasa Saito;Takayuki Katayama;J. Sawada;K. Kano;A. Asanome;Kae Takahashi;N. Sato;N. Hasebe
摘要
节段性颅颈肌张力障碍以眼睑痉挛和口下颌肌张力障碍为特征，也称为Meige综合征。目前的治疗策略，包括肉毒杆菌毒素（BTX）注射尚未达到可接受的水平。我们描述了阿立哌唑（阿普）、苯海索（THP）和BTX联合治疗3例节段性颅颈肌张力障碍患者的长期良好反应。3例患者的症状对阿普3-6 mg/d、THP 2-8 mg/d和BTX的联合治疗迅速反应。虽然患者需要每3-6个月接受一次BTX 50-100 IU注射，但他们的症状保持在令人满意的状态长达2年，没有任何不良反应。阿普具有显著改善肌张力障碍的潜力。THP有可能增强阿普的疗效，延长BTX的有效期。这可能是一个重要的必要条件，使所有三个代理一起成功的治疗。阿普、THP和BTX的联合治疗耐受性良好，可用于控制节段性颅颈肌张力障碍的症状，然而，这种联合治疗成功的原因尚不清楚。需要进一步长期随访以监测迟发性神经系统不良反应。
Abstract
Segmental craniocervical dystonia is characterized by blephalospasm and oromandibular dystonia and is also called Meige syndrome. The current treatment strategy including botulinum toxin (BTX) injections has not yet attained an acceptable level. We describe a long-term favorable response of a novel combination therapy with aripiprazole (ARP), trihexyphenidyl (THP), and BTX in three patients with segmental craniocervical dystonia. The symptoms of three patients responded promptly to the combination therapy with ARP 3–6 mg daily, THP 2–8 mg daily, and BTX. Although the patients were required to receive a BTX 50–100 IU injection every 3–6 months, their symptoms were kept in a satisfactory condition for up to 2 years without any adverse effects. ARP possesses the potential for dramatically improving dystonia. THP has the possibility to enhance the efficacy of ARP and prolong the effective period of BTX. It may be an important requisite to give all three agents together for a successful treatment. The combination therapy with ARP, THP, and BTX was well-tolerated and useful in controlling the symptoms of segmental craniocervical dystonia, however, the reason why this combination therapy succeeded is unknown. A further long-term follow-up is required to monitor the delayed neurological adverse effects.
影响因子：
4.1
作者：
LeDoux MS
通讯作者：
LeDoux MS